Color cases ought to be printed in colour to optimize their effectiveness. Towards the end of 2010, firms in the gene sequencing sector were driving competitive R&D plans to develop technologies and the in products race to sequence the entire human genome at a price of $1,000. It remained to be seen when the "$1,000 genome" would arrive, and despite all of the buzz surrounding the sector, it was still uncertain to investors who the business victor would be.
This case targets the development of third-generation sequencing as well as the four sections in the business: hardware, consumables, services, and interpretation. The case presents the development of sequencing technology, the history of the sector, as well as the business models of players in every single section.
PUBLICATION DATE: October 17, 2011 PRODUCT #: 812004-PDF-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
Aegis Analytical Corporations Strategic Alliances
Alto Chemicals Europe (A)
Deloitte & Touche Integrating Arthur Andersen
Skeleton in the Corporate Closet
Chabros International Group
Beyoncé
Singapore Metals Limited, Chinese Version
iMatari
Global wine wars 2009: New World Versus Old
FLYHT: Crossing the Chasm
